Physical and biological targeting of radiotherapy

Acta Oncologica, Supplement

Volumn 38, Issue 13, 1999, Pages 75-83

  Joensuu, Heikki ^a   Tenhunen, Mikko ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BORON DERIVATIVE; CALCIUM DERIVATIVE; HORMONE DERIVATIVE; IODINE 131; PHENYLALANINE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PHOSPHORUS 32; STRONTIUM 89; 4 BORONOPHENYLALANINE; BORON 10; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY IN 111; ETHELENEDIAMINE TETRAMETHYLENE PHOSPHONATE SAMARIUM 153 COMPLEX; HYDROXYETHYLIDENE DIPHOSPHONIC ACID RHENIUM 186 COMPLEX; IMMUNOTOXIN; IRIDIUM 192; MONOCLONAL ANTIBODY B1 I 131; MONOCLONAL ANTIBODY CC49 I 131; MONOCLONAL ANTIBODY CD20 I 131; MONOCLONAL ANTIBODY G250 I 131; MONOCLONAL ANTIBODY LYM 1 I 131; MONOCLONAL ANTIBODY TAG 72 I 131; PENTETREOTIDE IN 111; PLACEBO; RADIOISOTOPE; RHENIUM 186; SAMARIUM 153; SULFHYDRYL BORANE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

BONE METASTASIS; BRACHYTHERAPY; CANCER; CONFERENCE PAPER; DRUG METABOLISM; DRUG TARGETING; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; ACOUSTIC NEURINOMA; ANALGESIA; ARTICLE; B CELL LYMPHOMA; BONE CANCER; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; BONE PAIN; BRAIN ARTERIOVENOUS MALFORMATION; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CARCINOID; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG HALF LIFE; EXTERNAL BEAM RADIOTHERAPY; GAMMA KNIFE RADIOSURGERY; GAMMA RADIATION; GASTROINTESTINAL TOXICITY; GLIOMA; HADRON; HADRON THERAPY; HUMAN; INFECTION; INTENSITY MODULATED RADIATION THERAPY; KIDNEY CANCER; LEUKOCYTE COUNT; LEUKOPENIA; MENINGIOMA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOISOTOPE THERAPY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTICALLY GUIDED CONFORMAL FRACTIONATED RADIOTHERAPY; STEREOTAXIC RADIOTHERAPY; STEREOTAXIC SURGERY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL; BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; NEOPLASMS; NEUTRONS; RADIOIMMUNOTHERAPY; RADIOSURGERY; RADIOTHERAPY;

EID: 0032709586     PISSN: 11001704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. 1. Blomgren H, Lax I, Nǎslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995; 34; 861-70.
2. 2. Kondziolka D, Lunsford LD, McLaughlin MR, et al. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med 1998; 339: 1426-33.
3. 3. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 1998; 42; 581-9.
4. 4. Nahum AE, Dearnaley DP, Steel GG. Prospects for photon-beam radiotherapy. Eur J Cancer 1994; 30A: 1577-83.
5. 5. Laramore GE. The use of neutrons in cancer therapy: a historical prospective through the modern era. Semin Oncol 1997; 24: 672-85.
6. 6. Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat Res 1999; 151: 1-18.
7. 7. Bruland OS, Skretting A, Solheim OP, Aas M. Targeted radiotherapy of osteosarcoma using 153Sm-EDTMP. Acta Oncol 1996; 35: 381-4.
8. 8. Holmes RA. Radiopharmaceuticals in clinical trials. Semin Oncol 1993; 20: 22-6.
9. 9. Ben-Josef E, Porter AT. Radioisotopes in the treatment of bone metastases. Ann Med 1997; 29: 31-5.
10. 10. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for palliation of pain due to osseous metastases. JAMA 1995; 274: 420-4.
11. 11. Porter AT, McEwan AJB, Powe JE, et al. Results of randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-13.
12. 12. Quilty PM, Kirk D, Bolger JJ, at al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
13. 13. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-Bl antibody for B-cell lymphoma: an update on the Michigan phase I experience. J Nucl Med 1998; 39 (Suppl 8): 21-7.
14. 14. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lyra-1 antibody for fractionated radioimmunotherapv of non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 3246-56.
15. 15. Kramer EL, Liebes L, Wasserheit C, et al. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 anti-body in patients with advanced breast cancer. Clin Cancer Res 1998; 4: 1679-88.
16. 16. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131 -labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 1529-37.
17. 17. Falini B, Terenzi A, Liso A, Flenghi L, Solinas A, Pasqualucci L. Targeted antibodies in the treatment of lymphomas. Cancer Surv 1997; 30: 295-309.
18. 18. Laitinen JO, Kairemo KJA, Jekunen AP, Korppi-Tommola T, Tenhunen M. The effect of three dimensional activity distribution on dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma. Cancer 1997; 80: 2545-52.
19. 19. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-oc-treotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33: 652-8.
20. 20. Öberg K. Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist 1998; 3: 339-45.